Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANJIB P MOHANTY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1972561157
CMS profile
225424
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$63.41

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $63.41 4

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
NESTLE HEALTHCARE NUTRITION INC. $17.78 1
Celgene Corporation $16.50 1
ABBVIE INC. $14.79 1
Janssen Scientific Affairs, LLC $14.34 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANJIB P MOHANTY

NPI 1972561157 · CMS profile ID 225424

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972561157?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANJIB P MOHANTY, NPI 1972561157, CMS profile ID 225424. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972561157?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SANJIB P MOHANTY, NPI 1972561157, CMS profile ID 225424. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972561157?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SANJIB P MOHANTY, NPI 1972561157, CMS profile ID 225424, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1972561157?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $63.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $16.5010/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015060845 CMS
NESTLE HEALTHCARE NUTRITION INC. $17.7805/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012526323 CMS
ABBVIE INC. $14.7903/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997935039 CMS
Janssen Scientific Affairs, LLC $14.3403/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988545737 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40.24 3
PY2020 $11.69 1
PY2023 $63.41 4
PY2024 $369.04 8
PY2025 $58.60 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $16,867.90 7
PY2023 Principal investigator $35,411.83 8
PY2022 Principal investigator $4,250.50 8
PY2021 Recipient $5,984.30 2
PY2021 Principal investigator $65,975.02 27
PY2020 Principal investigator $63,774.31 52
PY2019 Principal investigator $115,243.22 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $1,199.00 12/22/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529101
Principal investigator 1 Gilead Sciences, Inc. $1,428.00 11/17/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529099
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,024.10 11/16/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 816776771
Principal investigator 1 Gilead Sciences, Inc. $12,537.00 10/20/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529097
Recipient Eli Lilly and Company $1,684.30 09/27/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 819445989
Principal investigator 1 Gilead Sciences, Inc. $3,470.00 09/22/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529095
Principal investigator 1 Gilead Sciences, Inc. $1,664.00 08/25/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529093
Principal investigator 1 Gilead Sciences, Inc. $3,298.00 08/23/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529091
Recipient Eli Lilly and Company $4,300.00 08/11/2021 Covered Recipient Physician A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 819446547
Principal investigator 1 Gilead Sciences, Inc. $17,921.00 07/21/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529089
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 07/06/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 816737463
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 07/06/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 816737473
Principal investigator 1 ABBVIE INC. $416.67 06/22/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792463691
Principal investigator 1 ABBVIE INC. $575.46 06/18/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 792463431
Principal investigator 1 Roche Products Limited $260.10 06/10/2021 Non-covered Recipient Entity
CHARLOTTE COLON AND RECTAL SURGERY ASSOCIATES PA
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 835948217
Principal investigator 1 Gilead Sciences, Inc. $1,664.00 04/26/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529087
Principal investigator 1 Gilead Sciences, Inc. $750.00 04/21/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529085
Principal investigator 1 Roche Products Limited $115.00 04/13/2021 Non-covered Recipient Entity
CHARLOTTE COLON AND RECTAL SURGERY ASSOCIATES PA
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 835948211
Principal investigator 1 ABBVIE INC. $416.67 04/01/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792441333
Principal investigator 1 ABBVIE INC. $416.67 04/01/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792441427
Principal investigator 1 ABBVIE INC. $500.45 03/24/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 792435163
Principal investigator 1 Gilead Sciences, Inc. $320.00 03/15/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803529083
Principal investigator 1 Roche Products Limited $3,193.20 03/11/2021 Non-covered Recipient Entity
CHARLOTTE COLON AND RECTAL SURGERY ASSOCIATES PA
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 835948207
Principal investigator 1 Roche Products Limited $75.00 02/23/2021 Non-covered Recipient Entity
CHARLOTTE COLON AND RECTAL SURGERY ASSOCIATES PA
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 835948201
Principal investigator 1 Roche Products Limited $497.70 02/02/2021 Non-covered Recipient Entity
CHARLOTTE COLON AND RECTAL SURGERY ASSOCIATES PA
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 835948195
Principal investigator 1 ABBVIE INC. $2,500.00 01/12/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792408725
Principal investigator 1 ABBVIE INC. $2,500.00 01/12/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792408749
Principal investigator 1 ABBVIE INC. $2,500.00 01/12/2021 Non-covered Recipient Entity
CHARLOTTE GASTROENTEROLOGY AND HEPATOLOGY
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792408789
Principal investigator 1 Roche Products Limited $733.00 01/07/2021 Non-covered Recipient Entity
CHARLOTTE COLON AND RECTAL SURGERY ASSOCIATES PA
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 835948189